Midwest Clinical Research

Dayton, United States· Est. 1994

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ohio Clinical Trials (OCT) is a well-established, privately-held clinical research site and service provider with nearly three decades of operational history. It possesses a significant competitive advantage through its owned 12,000 sq ft, 60+ bed inpatient facility in Columbus, Ohio, enabling complex early-phase trials including first-in-human, hepatic/renal impairment, and human abuse liability studies. As part of the ERG portfolio network, OCT leverages deep therapeutic expertise across multiple areas and a proprietary patient engagement app (MyTrial) to deliver efficient, high-quality trial execution for its biopharma clients. The company is firmly in a revenue-generating services business model, dependent on the flow of sponsored clinical trial contracts.

CardiovascularMetabolic Disorders (e.g., Obesity, Diabetes)Infectious DiseaseCentral Nervous System (CNS)UrologyGastroenterologyEndocrinology

Technology Platform

Integrated clinical trial execution platform combining a large, company-owned inpatient research facility (12,000 sq ft, 60+ beds) with a proprietary patient engagement and trial management application (MyTrial App). Includes on-site lab, secure drug storage, emergency backup systems, and a network of therapeutic area specialists.

Opportunities

Growing demand for complex early-phase trials (First-in-Human, hepatic/renal impairment) and Human Abuse Liability (HAL) assessments presents a significant opportunity.

Expansion of digital trial management via the MyTrial App can improve recruitment efficiency and participant retention, creating a competitive edge.

Risk Factors

Revenue is entirely project-based and susceptible to biopharma R&D budget cycles.

Operational risks include patient safety incidents, recruitment delays, and regulatory compliance failures, any of which could damage reputation and financial stability.

High fixed costs of maintaining a large dedicated facility create financial pressure during contract gaps.

Competitive Landscape

Competes with other dedicated Phase I units, site management organizations (SMOs), academic medical centers, and large global CROs. Differentiation is achieved through its owned inpatient facility, deep early-phase expertise, and niche capabilities in abuse liability and organ impairment studies. The ERG network affiliation may provide scale advantages in bidding and resource sharing.